219 results on '"Balas, B"'
Search Results
2. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
3. Perceptions of heart failure symptoms, disease severity, treatment decision-making and side effects by patients and cardiologists: a multinational survey in a cardiology setting
4. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
5. Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey
6. To which world regions does the valence–dominance model of social perception apply?
7. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment
8. Can naive observers detect suicidality in face images? A replication and extension of Kleiman and Rule (2013)
9. Pioglitazone in the treatment of NASH: the role of adiponectin
10. Using social face-space to estimate social variables in real and artificial faces
11. ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC
12. PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANY
13. P6530What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels
14. P907Titration patterns and clinical characteristics of patients prescribed sacubitril/valsartan in the primary care and cardiology settings in Germany
15. PS02.22 Alectinib Following Prior ALK Tyrosine Kinase Inhibitor (TKI) Therapy: Results from the US Expanded Access Program (EAP)
16. P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC
17. Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
18. Hospitalisations Among A Cohort Of Patients With Heart Failure Versus An Age- And Sex-Matched Cohort Without Heart Failure In England: A Comparative Study Using Cprd Data
19. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
20. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
21. CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC
22. P608Characteristics of patients with heart failure prescribed sacubitril/valsartan in the primary care and cardiology settings in Germany
23. P1467Characteristics of early sacubitril/valsartan users in US electronic health record data
24. P4395Characteristics of patients with heart failure prescribed sacubitril/valsartan in the primary care setting in Germany
25. Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)
26. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
27. 410O_PR - Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
28. PHS111 - Hospitalisations Among A Cohort Of Patients With Heart Failure Versus An Age- And Sex-Matched Cohort Without Heart Failure In England: A Comparative Study Using Cprd Data
29. 1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
30. 1299O_PR - Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
31. 1346P - CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC
32. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
33. Both own and other object shadows compress perceived distance
34. Invariant texture recognition depends on high-order statistics
35. The inversion effect as a function of orientation information in emotional face and body recognition
36. Early visual ERP components are sensitive to natural texture appearance
37. Face animacy does not impact the N170 inversion effect
38. The effect of contrast negation on real/artificial face discrimination
39. 1263P - Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)
40. Approche spatiale de la pollution par les nitrates
41. Personal familiarity influences the processing of upright and inverted faces in infants.
42. Gestion de l'irrigation au niveau de l'exploitation agricole
43. [Irrigation management at the farm level]
44. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment
45. Emotion recognition (sometimes) depends on horizontal orientations
46. Invariant properties of detecting personal familiarity in "thin slices" of behavior
47. Cast-body shadows compress perceived distances
48. Face animacy perception is species-specific
49. Gestion de l'eau à l'échelle de l'exploitation agricole
50. Water management at farm level
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.